Back to results
US 9,802,948 B2Granted
Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
AssigneeTrustees of Boston Univeristy
InventorsUlla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III′) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
Claims7
A compound of formula (III′), wherein the Formula (III′) has the structure:
- wherein:
- R1′ is an aryl substituted with at least one C1-C6 alkoxyl and at least one di(C1-C24alkyl)amino, halogen or C2-C8alkenyl, wherein the substituted aryl can be optionally further substituted with halogen, C1-C4 alkyl, C1-C4haloalkyl, C1-C4 heteroalkyl, di(C1-C24alkyl)amino or combinations thereof;
- R2 and R3 are hydrogen or R2 and R3 together form a second bond between the carbons to which they are attached;
- R4 is hydrogen;
- R5 is selected from the group consisting of hydrogen and C1-C6 alkyl;
- R6 and R7 are each independently selected from the group consisting of hydrogen, F, Br, Cl and I;
- R10 and R11 are each independently selected from the group consisting of hydrogen, F, Br, Cl, and I;
- or enantiomers, prodrugs, derivatives, and pharmaceutically acceptable salts thereof, and
- wherein the compound is capable of inhibiting late SV40 factor (LSF).
6 more elements
Dependencies are inferred from the claim text.